Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers

por Chen, Rui, Zhao, Wei-qing, Fang, Cheng, Yang, Xin, Ji, Mei
Publicado 2020

Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report

por Fang, Cheng, Zhang, Chu, Zhao, Wei-Qing, Hu, Wen-Wei, Wu, Jun, Ji, Mei
Publicado 2019

CD40 mutant expression and its clinical significance to prognosis in gastric cancer patients

por Zhao, Wei-Qing, Li, Xiao-Dong, Shi, Hong-Bing, Wu, Jun, Zhao, Jie-Min, Ji, Mei, Wu, Chang-Ping
Publicado 2014

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation

por Ji, Mei, Liu, Yan, Li, Qing, Li, Xiao-Dong, Zhao, Wei-Qing, Zhang, Hanze, Zhang, Xiaofei, Jiang, Jing-Ting, Wu, Chang-Ping
Publicado 2015

Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1–IL‐8 signaling‐mediated epithelial–mesenchymal transition in lung adenocarcinoma

por Yang, Xin, Chen, Rui, Chen, Yan, Zhou, You, Wu, Chen, Li, Qing, Wu, Jun, Hu, Wen‐wei, Zhao, Wei‐qing, Wei, Wei, Shi, Jun‐tao, Ji, Mei
Publicado 2022